Io Biotech, Inc. Financials
This page shows Io Biotech, Inc. (IOBT) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Io Biotech, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Io Biotech, Inc. passes 2 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.
Io Biotech, Inc. reported a net loss of $95.5M while operations used $82.3M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Io Biotech, Inc.'s EBITDA was -$94.9M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 4.0% from the prior year.
Io Biotech, Inc. reported -$95.5M in net income in fiscal year 2024. This represents a decrease of 10.9% from the prior year.
Not reported for fiscal year 2024.
Cash & Balance Sheet
Io Biotech, Inc. recorded an outflow of $82.4M in free cash flow in fiscal year 2024, representing a cash shortfall after capex. This represents a decrease of 14.3% from the prior year.
Io Biotech, Inc. held $60.0M in cash against $0 in long-term debt as of fiscal year 2024.
Not reported for fiscal year 2024.
Margins & Returns
Io Biotech, Inc.'s ROE was -203.1% in fiscal year 2024, measuring profit generated per dollar of shareholder equity. This is down 138.5 percentage points from the prior year.
Not reported for fiscal year 2024.
Not reported for fiscal year 2024.
Not reported for fiscal year 2024.
Capital Allocation
Io Biotech, Inc. invested $71.5M in research and development in fiscal year 2024. This represents an increase of 5.4% from the prior year.
Io Biotech, Inc. invested $44K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 86.4% from the prior year.
Not reported for fiscal year 2024.
IOBT Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|---|
| R&D Expenses | N/A | $71.5M+5.4% | $67.8M+44.4% | $47.0M+55.8% | $30.2M+256.2% | $8.5M |
| SG&A Expenses | N/A | $23.7M+0.3% | $23.6M-3.4% | $24.4M+120.5% | $11.1M+559.3% | $1.7M |
| Operating Income | N/A | -$95.2M-4.1% | -$91.4M-28.0% | -$71.4M-73.2% | -$41.2M-306.4% | -$10.1M |
| Interest Expense | N/A | N/A | N/A | $302K-16.3% | $361K+1288.5% | $26K |
| Income Tax | N/A | $1.4M+69.4% | $852K-33.1% | $1.3M+1772.1% | $68K | N/A |
| Net Income | N/A | -$95.5M-10.9% | -$86.1M-20.5% | -$71.5M-5.3% | -$67.9M-463.7% | -$12.0M |
| EPS (Diluted) | — | -$1.45 | -$1.98 | -$2.48 | -$17.30 | N/A |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit.
TTM is the trailing twelve months, Q4 FY2024 through Q3 FY2025, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
IOBT Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|
| Total Assets | $67.7M-55.1% | $150.7M-0.7% | $151.8M-31.7% | $222.3M+3832.2% | $5.7M |
| Current Assets | $65.0M-55.9% | $147.3M-0.7% | $148.2M-33.2% | $221.7M+3835.0% | $5.6M |
| Cash & Equivalents | $60.0M-58.1% | $143.2M+0.4% | $142.6M-32.6% | $211.5M+6112.4% | $3.4M |
| Total Liabilities | $20.7M+17.8% | $17.6M+35.6% | $13.0M+25.0% | $10.4M-74.7% | $41.0M |
| Current Liabilities | $19.5M+24.0% | $15.7M+47.2% | $10.7M+3.6% | $10.3M+237.9% | $3.0M |
| Long-Term Debt | $0 | N/A | N/A | N/A | N/A |
| Total Equity | $47.0M-64.7% | $133.2M-4.1% | $138.9M-34.5% | $211.9M+700.3% | -$35.3M |
| Retained Earnings | -$359.3M-36.2% | -$263.8M-48.4% | -$177.7M-67.2% | -$106.3M-176.8% | -$38.4M |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill.
IOBT Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -$81.0M | -$82.3M-14.8% | -$71.7M-20.1% | -$59.7M-46.9% | -$40.6M-308.3% | -$10.0M |
| Capital Expenditures | $69K | $44K-86.4% | $323K-53.2% | $690K+351.0% | $153K | N/A |
| Free Cash Flow | -$81.1M | -$82.4M-14.3% | -$72.1M-19.3% | -$60.4M-48.1% | -$40.8M | N/A |
| Investing Cash Flow | -$69K | -$44K+86.4% | -$323K+53.2% | -$690K-351.0% | -$153K | N/A |
| Financing Cash Flow | N/A | N/A | $71.9M | N/A | $253.0M+4857.9% | $5.1M |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q4 FY2024 through Q3 FY2025, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
IOBT Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|
| Return on Equity | -203.1%-138.5pp | -64.6%-13.2pp | -51.5%-19.4pp | -32.0% | N/A |
| Return on Assets | -141.1%-84.0pp | -57.1%-10.1pp | -47.1%-16.5pp | -30.5%+182.5pp | -213.0% |
| Current Ratio | 3.33-6.0x | 9.37-4.5x | 13.88-7.6x | 21.52+19.7x | 1.85 |
| Debt-to-Equity | 0.00-0.1x | 0.130.0x | 0.090.0x | 0.05 | N/A |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Io Biotech, Inc. Ranks
Frequently Asked Questions
Is Io Biotech, Inc. profitable?
No, Io Biotech, Inc. (IOBT) reported a net income of -$95.5M in fiscal year 2024.
What is Io Biotech, Inc.'s EBITDA?
Io Biotech, Inc. (IOBT) had EBITDA of -$94.9M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Io Biotech, Inc. have?
As of fiscal year 2024, Io Biotech, Inc. (IOBT) had $60.0M in cash and equivalents against $0 in long-term debt.
What is Io Biotech, Inc.'s return on equity (ROE)?
Io Biotech, Inc. (IOBT) has a return on equity of -203.1% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.
What is Io Biotech, Inc.'s free cash flow?
Io Biotech, Inc. (IOBT) recorded an outflow of $82.4M in free cash flow during fiscal year 2024. This represents a -14.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Io Biotech, Inc.'s operating cash flow?
Io Biotech, Inc. (IOBT) recorded an outflow of $82.3M in operating cash flow during fiscal year 2024, representing cash used by core business activities.
What are Io Biotech, Inc.'s total assets?
Io Biotech, Inc. (IOBT) had $67.7M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Io Biotech, Inc.'s capital expenditures?
Io Biotech, Inc. (IOBT) invested $44K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Io Biotech, Inc. spend on research and development?
Io Biotech, Inc. (IOBT) invested $71.5M in research and development during fiscal year 2024.
What is Io Biotech, Inc.'s current ratio?
Io Biotech, Inc. (IOBT) had a current ratio of 3.33 as of fiscal year 2024, which is generally considered healthy.
What is Io Biotech, Inc.'s debt-to-equity ratio?
Io Biotech, Inc. (IOBT) had a debt-to-equity ratio of 0.00 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Io Biotech, Inc.'s return on assets (ROA)?
Io Biotech, Inc. (IOBT) had a return on assets of -141.1% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Io Biotech, Inc.'s cash runway?
Based on fiscal year 2024 data, Io Biotech, Inc. (IOBT) had $60.0M in cash against an annual operating cash burn of $82.3M. This gives an estimated cash runway of approximately 9 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Io Biotech, Inc.'s Piotroski F-Score?
Io Biotech, Inc. (IOBT) has a Piotroski F-Score of 2 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Io Biotech, Inc.'s earnings high quality?
Io Biotech, Inc. (IOBT) reported a net loss of $95.5M while operations used $82.3M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.